RCS - Ondine Biomedical - Ondine to present Health Economic Data at ICPIC

Ondine BiomedicalAnnouncement

03/09/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250903:nRSC8084Xa&default-theme=true

RNS Number : 8084X  Ondine Biomedical Inc.  03 September 2025

3 September 2025

Ondine to present Health Economic Data at ICPIC 2025

Health Economics Study on Ondine's Steriwave® Selected for Oral Presentation
at ICPIC 2025 in Geneva

Ondine Biomedical Inc. (LON: OBI) announces that it was invited to make an
oral presentation about health and economic benefits of Steriwave nasal
photodisinfection at the 12th International Conference on Prevention &
Infection Control (ICPIC) in Geneva, Switzerland. ICPIC is recognized as the
leading conference for infection prevention and control, attracting global
experts and healthcare innovators. The Company's abstract detailing a health
economic analysis by the York Health Economics Consortium (YHEC) has been
accepted and upgraded to an oral presentation (session O06). The annual global
conference will be held 16-19 September 2025, in Geneva, Switzerland.

This presentation will highlight how Steriwave nasal photodisinfection
significantly reduces costs associated with surgical site infections (SSIs),
demonstrated in both a patient series of elective hip and knee replacements at
Mid Yorkshire Teaching NHS Trust (MYTT) and more extensively in two separate
health economic models using literature-derived data across multiple surgical
specialties. YHEC's research shows that Steriwave not only improves patient
outcomes but also delivers substantial net savings by preventing SSIs in major
surgeries.

Simon Sinclair, Chief Medical Officer of Ondine Biomedical said:

"These results are significant for hospital administrators and patients alike,
especially with the unprecedented strain on healthcare systems worldwide.
Preventing infections is not just about patient safety, it is a critical
strategy for conserving resources, improving hospital efficiency, and
combating antimicrobial resistance. The Mid Yorkshire data, combined with our
rigorous economic modeling, shows how a simple, rapid intervention like
Steriwave can have a profound impact on patient outcomes and reduce the
economic burden of surgical site infections. This ICPIC recognition
underscores Ondine's ongoing commitment to improving hospital infection
control with cost-effective healthcare solutions."

Steriwave is a non-invasive and pain-free nasal decolonisation treatment that
uses a proprietary light-activated antimicrobial agent to destroy harmful
pathogens-including bacteria, viruses, and fungi-in the nose. Steriwave
treatment involves applying a proprietary photosensitive agent to each nostril
with a nasal swab, followed by illumination with a specific wavelength of red
light for five minutes. The treatment is effective immediately, takes less
than five minutes, and preserves the natural microbiome while offering
immediate microbial reduction without the development of resistance. It is
widely used in hospitals across Canada and increasingly in the UK.

 

Enquiries:

 Ondine Biomedical Inc.                                      www.ondinebio.com
 Carolyn Cross, CEO                                          +1 604 669 0555

or via Vane Percy & Roberts

 Strand Hanson Limited (Nominated & Financial Adviser)
 James Harris, Richard Johnson                               +44 (0)20 7409 3494

 Peel Hunt LLP (Broker & Joint Financial Advisor)
 James Steel, Dr. Chris Golden                               +44 (0)20 7418 8900

 Vane Percy & Roberts (Media Contact)
 Simon Vane Percy                                            +44 (0)77 1000 5910

 

 

About Ondine Biomedical Inc.

Ondine Biomedical Inc. is a Canadian life sciences company and leader in
light-activated antimicrobial therapies ('photodisinfection') for the
prevention and treatment of infections, including those caused by
multidrug-resistant organisms. Ondine has a pipeline of investigational
products, based on its proprietary photodisinfection technology, in various
stages of development.

Ondine's nasal photodisinfection system has a CE mark in Europe and is
approved in Canada, Australia, Mexico and several other countries under the
name Steriwave(®). In the US, it has been granted Qualified Infectious
Disease Product designation and Fast Track status by the FDA and is currently
undergoing clinical trials for regulatory approval. Products beyond nasal
photodisinfection include therapies for a variety of medical indications such
as chronic sinusitis, ventilator-associated pneumonia, burns and other
indications.

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAEXLBBEKLXBBV